BRIDGEWATER, N.J., April 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2023 financial results on Thursday, May 4, 2023.
Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, May 4, 2023, to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (833) 470-1428 (U.S.) or (929) 526-1599 (international) and referencing access code 468531. The call will also be webcast live on the company's website at www.insmed.com.
A replay of the conference call will be accessible approximately 30 minutes after its completion through June 3, 2023, by dialing (866) 813-9403 (U.S.) or (+44) 204-525-0658 (international) and referencing access code 281829. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.
Executive Director, Investor Relations
Associate Director, Investor Relations
Executive Director, Corporate Communications
SOURCE Insmed Incorporated